Building a Regulatory Intelligence Function

A regulatory intelligence (RI) function is the part of a clinical-research or product-development organization that watches the external regulatory environment, decides which of the thousands of things that happen in it actually matter, and turns the relevant ones into a documented input to submission strategy. It is not a newsletter, a shared inbox of forwarded FDA emails, or a subscription to a vendor database. Those are sources. RI is the workflow that turns sources into decisions.

This page covers three things a working RI function needs and most vendor overviews of the topic skip: a real taxonomy of what counts as an input, where each input actually gets published and how it is monitored, and a triage workflow that moves an item from "someone noticed it" to "it changed something."

Regulatory intelligence is not regulatory affairs

The two functions get collapsed together constantly, including in vendor marketing, and the distinction is the actual organizing principle for building either one correctly.

Regulatory affairs is the execution layer: the office or role that determines which regulatory frameworks apply to a given study or product, prepares and files the submissions those frameworks require (an IND under 21 CFR Part 312, a BLA, a 510(k)), and keeps the regulatory record current for the life of the project or product.

Regulatory intelligence is the input layer that feeds RA’s decisions. RI does not file anything with an agency. It answers a narrower, prior question: what is changing in the external regulatory environment that RA’s current strategy, an open submission, or an SOP needs to account for? A well-run RI function makes RA’s strategy decisions better-informed and earlier; it does not make them.

Confusing the two produces the failure mode this page exists to prevent: an organization that reads every FDA guidance document the day it posts but has no defined path from "we read it" to "we changed the CMC section of the BLA we’re drafting." That gap is where RI functions fail quietly — not from missing information, but from information that never gets triaged into a decision.

The source taxonomy: six real input types

An RI programme’s inputs are not interchangeable. Each has a different publication mechanism, a different draft-vs-final status model, and a different monitoring method. Treating them as one undifferentiated stream of "regulatory news" is the first design mistake.

1. FDA and EMA guidance documents — and their draft-vs-final status

FDA guidance is published at fda.gov/regulatory-information/search-fda-guidance-documents and carries an explicit status: draft (open for public comment, not binding, signals FDA’s current thinking) or final. A draft guidance is itself an intelligence signal — it tells you what FDA is likely to expect before it’s enforceable, which is exactly the lead time a submission strategy can use. FDA also publishes an annual guidance agenda by center (CDER, CBER, CDRH) listing guidance documents planned for the coming year, which is a monitoring input in its own right, not just the finished documents. Monitor via FDA’s guidance-document email/RSS subscription rather than checking the search page manually.

EMA scientific guidelines follow a comparable draft-vs-adopted lifecycle, published at ema.europa.eu. Where a guideline is jointly developed through ICH, the relevant status marker is the ICH step number: Step 2 is draft (released for public consultation), Step 4 is the finalized harmonised text, and Step 5 is the point at which each region (FDA, EMA, PMDA and others) formally adopts it into their own regulatory framework — a guideline can sit at Step 4 as final ICH text while still working through regional Step 5 adoption in a given jurisdiction, which matters if your submission strategy depends on which region has actually implemented it.

2. Dockets on Regulations.gov

Proposed rules, draft guidance notices, and public-comment opportunities are published as dockets on Regulations.gov (FDA’s dockets are managed through the Federal Dockets Management System, FDMS, which sits on that same platform). Each individual docket has a "Sign up for Email Alerts" option where you choose a frequency — daily, weekly, or monthly — so a real monitoring setup is a per-docket subscription, not a generic keyword search repeated by hand. The docket itself is also where competitors’ and professional societies’ public comments on a proposed rule are visible, which is a second, easy-to-miss intelligence source living inside the same docket.

3. Advisory committee meeting materials

FDA advisory committee meetings are announced in advance via a Federal Register notice, and FDA posts briefing documents (the agency’s own briefing book plus the sponsor’s, where applicable), meeting transcripts, and webcasts on the committee’s page at fda.gov once available. The briefing documents in particular are a distinct intelligence source from the guidance-document stream: they show FDA’s live reasoning and question framing on a specific product or class, ahead of any resulting guidance or approval decision, and are often the earliest public signal of how the agency is thinking about a novel pathway or endpoint.

4. Competitor approvals and Complete Response Letters

Drugs@FDA carries approval letters, labeling, and review documents for approved products. For unfavorable outcomes, FDA now publishes Complete Response Letter (CRL) text for drug and biologic NDA/BLA actions through an openFDA database, with confidential commercial and trade-secret information redacted under 21 CFR Part 20 — this is a real change from FDA’s earlier posture of not confirming a pending application’s existence before an approval action. Coverage is not comprehensive (FDA states it publishes archival batches over time, weighted toward recent years), so treat a CRL search as a real but incomplete window, not an exhaustive one. This applies to drugs and biologics only; device CRLs are not covered by that same database. See the full mechanics on reading a Complete Response Letter.

5. Professional-society position statements and technical resources

Bodies like the Regulatory Affairs Professionals Society (RAPS) publish position statements, technical resources, and practitioner guidance on the regulatory landscape itself — a distinct input from what any single agency publishes, because it reflects cross-company practitioner consensus (or disagreement) forming in real time, often ahead of formal agency action.

6. Everything you monitor should land in one intake log

Whatever the source, every item needs to hit a single structured log before triage starts — source, publication date, item type (draft guidance, final guidance, docket notice, advisory-committee material, CRL, position statement), and a one-line description. Six separate people separately reading six separate sources with no shared log is not an RI function; it’s six individual habits that don’t compound into organizational intelligence.

The triage workflow: from noticed to actioned

This is the part a vendor’s product page skips, because it isn’t about their tool — it’s the actual discipline that makes RI worth the headcount. A working triage workflow has five stages, each with a real gate, not just a stage name.

Stage	Question the stage answers	Output
1. Capture	Did we log it, with source and date?	One line in the shared intake log
2. Relevance screen	Does this touch a product, programme, or pathway we actually have?	Binary: screened out (logged, no further action) or advanced
3. Impact assessment	Who is the right owner (RA lead, clinical, quality, CMC), and what does this actually change if true?	Named owner, assessed severity/urgency, target response date
4. Disposition	What does the assessment produce?	One of: no action (filed for reference); input to an open or upcoming submission strategy; an SOP or work-instruction update; escalation to a portfolio-level steering group
5. Close the loop	Was the disposition actually implemented, and did the stakeholders who needed to know, know?	Documented closure, dated, linked back to the log entry

The stage that actually distinguishes a real RI function from a reading habit is 4: disposition. "We discussed the new draft guidance in a meeting" is not a disposition. A disposition is a specific, attributable change — the CMC comparability section of a BLA gets redrafted before submission because a new draft guidance changed FDA’s stated expectations; a monitoring plan template gets revised because ICH E6(R3) redefined what "critical to quality" means; a go/no-go recommendation to a portfolio committee changes because a competitor’s CRL revealed a shared class-level safety concern. If an item can’t be traced to one of those four outcomes, it was screened correctly at stage 2 or 3 — it should not sit open indefinitely as an unresolved "maybe."

Stage 5 is the one organizations skip first once budget pressure hits, and it’s the one that makes RI compound rather than reset every cycle: without a closed, dated record of what a given guidance document actually changed, the next person doing the same relevance screen six months later has no institutional memory to draw on and re-does the same assessment from zero.

Where a professional body has actually published on this

RAPS maintains a Regulatory Competency Framework (2021, with a 2022 performance-criteria addendum) that organizes regulatory-profession competencies across four professional/career levels, intended for planning training and professional development rather than as an organizational maturity model for an RI function specifically — worth knowing it exists, but it is a competency map for individuals, not a blueprint for structuring a department.

The more directly relevant resource is RAPS’s 2026 volume Regulatory Intelligence Reimagined (28 chapters, edited by Linda Bowen, MS, RAC, FRAPS), which includes chapters titled "Establishing a Robust Regulatory Intelligence Function" and "Establishing Key Performance Indicators to Advocate for a Dedicated Regulatory Policy and Intelligence Function," drawing on practitioners across biopharma, medical devices, and CROs. This page does not reproduce that book’s specific framework or KPI recommendations — only its title, chapter structure, editor, and publication year were verified directly against RAPS’s own listing — but it is the real, current, professional-body treatment of exactly this build-the-function question, and worth going to directly rather than relying on a secondary summary.

What this looks like in practice

A minimum-viable RI function for a single-product or early-stage sponsor is not a department; it is one owner running the five-stage workflow above against the six source types, with per-docket email alerts doing the capture work automatically wherever a source supports them (Regulations.gov dockets, FDA guidance RSS/email) and a manual weekly check for the sources that don’t (advisory committee calendars, CRL database queries, professional-society publications). The workflow scales by adding named owners per source type and a recurring cross-functional review of open dispositions — not by adding more sources to watch. A team that adds a seventh and eighth data feed before it has a working disposition stage for the first six is solving the wrong problem.

Frequently asked questions

Is regulatory intelligence the same as regulatory affairs?
No. RI monitors the external environment and assesses relevance; RA uses that intelligence, plus its own strategy and regulatory expertise, to actually prepare and file submissions and manage the regulatory record. See the distinction above.

Do I need dedicated software to run an RI function?
Not to start. A single intake log plus per-docket/per-guidance email alerts covers most of the capture stage for a small programme. Commercial RI platforms (Thomson Reuters Regulatory Intelligence, IQVIA Regulatory Intelligence, and comparable tools) add cross-jurisdiction aggregation and search at scale, which becomes worth evaluating once the number of products, markets, or sources outgrows manual per-source monitoring — but the triage workflow above is the part software does not do for you.

How often should each source be checked?
Set the check frequency by the source’s own publication cadence and subscription options, not a blanket schedule: Regulations.gov docket alerts support daily, weekly, or monthly frequency per docket; FDA/EMA guidance subscriptions push on publication; advisory committee calendars and the CRL database don’t offer push alerts, so those need a recurring manual check (weekly is a reasonable default for an active therapeutic area).

Regulatory Intelligence: Building a Monitoring Function